Zimmer Biomet stock holds at USD 91.62 as BMO keeps target
Published on 09/29/2026 at 08:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Zimmer Biomet stock (ISIN US98956P1021) closed at USD 91.62 on the NYSE on September 28, 2026, up 0.64 percent for the session. The latest catalyst is BMO Capital's unchanged USD 96.00 price target after reviewing the company's iodine-coated hip implant launch in Japan.
BMO keeps target at USD 96.00
According to Investing.com on September 28, 2026, BMO Capital reiterated a Market Perform rating and kept its USD 96.00 target. That target is 4.78 percent above the September 28 closing price, leaving the analyst view modestly above the market quotation.
BMO's Japan thesis centers on an iodine-coated hip implant, but the same report identified manufacturing capacity as a near-term constraint. The commercial opportunity therefore depends on Zimmer Biomet converting product demand into supply while it develops its broader orthopedic portfolio.
Second quarter beat expectations
Zimmer Biomet's second-quarter 2026 adjusted EPS was USD 2.07, compared with a USD 2.01 consensus estimate. Yahoo Finance reported on September 4, 2026, that adjusted EPS beat consensus by 3 percent, while the adjusted figure was unchanged from the year-earlier quarter.
Revenue reached USD 2.18 billion in Q2 2026, up 4.80 percent year over year and above the USD 2.13 billion consensus cited by Yahoo Finance. The strongest reported category was Technology and Data, Bone Cement and Surgical, where revenue rose 21.10 percent to USD 199.40 million.
Guidance sets the next test
Management's fiscal 2026 adjusted EPS guidance stands at USD 8.47-8.59 per share, versus the previous USD 8.40-8.55 range. Reported revenue growth guidance was also raised to 3.90-4.90 percent from 2.50-4.50 percent, giving investors a measurable benchmark for the next results update.
Zimmer Biomet operates in medical devices, with orthopedic reconstruction, trauma, sports medicine, biologics, robotics and digital products. The mix gives the Japan implant opportunity a specific role: it adds a growth avenue while the established portfolio remains the main earnings base.
Stock remains below its yearly high
Zimmer Biomet stock closed at USD 91.62 on September 28, 2026, with a 52-week range of USD 79.12 to USD 106.88 and a market capitalization of USD 17.7 billion. The session volume was 1,630,000 shares, placing the BMO target and the latest quarterly beat against a stock still below its yearly high.
Zimmer Biomet stock facts
- Company: Zimmer Biomet Holdings, Inc.
- ISIN: US98956P1021
- Ticker: ZBH
- Trading venue: NYSE
- Price (as of September 28, 2026): Closing price USD 91.62
- Market capitalization: USD 17.7 billion (as of September 28, 2026)
- 52-week range: USD 79.12-106.88 (as of September 28, 2026)
- Sector / Industry: Healthcare / Medical Devices
- Index membership: S&P 500
